IMCgp100 is an ImmTAC therapeutic targeting the melanoma-associated antigen gp100. It is currently undergoing a pivotal clinical study as a monotherapy for the treatment of patients with metastatic uveal melanomas.
Combination studies with IMCgp100 and other immunotherapies, including a Phase I/II study with checkpoint inhibitors durvalumab and tremelimumab from MedImmune (AstraZeneca), for patients with metastatic cutaneous melanoma, are currently recruiting.
IMCgp100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of uveal melanoma.
For more information on clinical trials involving IMCgp100 see clinicaltrials.gov.
If you have additional questions, please send them to Patientinfo@immunocore.com
If you are a medical professional and require further information about Immunocore, our clinical research or clinical trials, please send an email to firstname.lastname@example.org
If you are a patient and seeking information about clinical trials, please send an email to Patientinfo@immunocore.com.
Patients are encouraged to contact their doctor ahead of contacting Immunocore including for questions regarding suitability or criteria for participating in a clinical trial or safety issues.